The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index; 33 of the 49 sources its claims cite were checked for support.
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
Open accessAbstract
The development of drugs targeting Nutrient Stimulated Hormone receptors has ushered in a dramatic change in our approach to weight management because of their ability to achieve weight losses of 10%, 20%, even 30% in significant numbers of patients. Additionally, disease modifying properties of these medications are compelling. Indications now include cardiovascular risk reduction, obstructive sleep apnea and diabetes management, and emerging evidence supports efficacy for heart failure and chronic kidney disease. These medications would need to be taken long term and the population being treated will be older than the traditional weight management patient. Emerging evidence cautions that the loss of excessive lean mass with some of the newer medications may be problematic. This is not a concern for most patients who will need the medications, but it is a concern in an older population, since loss of muscle and bone accelerates and progresses past age 60. Of weight lost with semaglutide, approximately 45% is from lean mass, while with tirzepatide, it is 25%. Going forward, combining another NuSH such as glucagon or amylin with the GLP-1 receptor agonists may lessen loss of lean mass. Another approach under study is the use of MAPi - myostatin-activin pathway inhibitors. Promising results with bimagrumab are spurring investigaton in this area. For the full potential of disease modification to be achieved, it's a given that we must demonstrate safe, long term body composition improvement when the new medications are deployed, especially in the older population. This narrative review discusses the justification for focus on lean mass preservation and reviews the status of relevant drugs in development.
Overview
CoChat Summary
TL;DR
This narrative review argues that highly effective NuSH-based obesity drugs (semaglutide, tirzepatide) produce major weight loss and disease-modifying benefits but also raise concern about excessive lean-mass loss, especially in older adults. It reviews emerging strategies—NuSH combinations, myostatin-activin pathway inhibitors, and selective androgen receptor modulators—that may preserve muscle during weight loss.
Key findings
- Semaglutide and tirzepatide produce large weight reductions: in STEP 1, semaglutide gave −14.9% vs −2.4% for placebo at week 68; in SURMOUNT-1, tirzepatide 5, 10, and 15 mg gave −15.0%, −18.5%, and −20.9% vs −2.4% for placebo at week 72. More patients achieved 10%/15%/20% weight loss with tirzepatide (90.1%/78.2%/62.9%) than semaglutide (74.8%/54.8%/34.8%).
- Body-composition substudies indicate differential lean loss: approximately 45% of weight lost with semaglutide was lean mass, versus 25.7% with tirzepatide, despite greater overall weight loss with tirzepatide. The review states that no studies have yet evaluated bone and muscle mass with these drugs; DEXA reports only lean and fat compartments.
- Long-term use appears necessary: in the STEP 1 extension, after withdrawal, net weight losses at week 120 were −5.6% for semaglutide and −0.1% for placebo; STEP 4 and SURMOUNT 4 showed weight regain and recidivism of health benefits after stopping.
- Muscle-preservation candidates show early signals: in 168 older adults with overweight/obesity receiving semaglutide, enobosarm reduced mean percentage lean-mass loss (−1.2% vs −4.1% for placebo) and loss of 10% Stair Climb Power (19.4% vs 42.6%). In a 48-week bimagrumab study (n=77), fat mass fell −20.5% vs −0.5% for placebo, lean mass rose +3.6% vs −0.8%, and A1c fell −0.76% vs −0.04%.
Methods
- Narrative review of current efficacy and safety profiles of NuSH-derived obesity medications, including GLP-1 receptor and GIP receptor agonists, and their disease-modifying attributes.
- Discusses potential lean-mass sparing by targeting GIP, amylin, and glucagon, and reviews myostatin-activin pathway inhibitors (MAPi) and selective androgen receptor modulators (SARM).
- Evidence is drawn from cited phase 3 trials, body-composition substudies, and selected press releases/registry entries; no new primary data or systematic search is reported.
Limitations
- The paper states that body-composition effects of semaglutide and tirzepatide have not been extensively studied, that no studies have evaluated bone and muscle mass with these drugs, and that more studies with greater definition of muscle and bone effects are needed.
- The paper states that SELECT fracture findings were inconclusive and require additional data, and that evidence for SARM use is sparse.
- Evident from the text: this is a narrative review relying on cited trials, unpublished top-line results, and web links; some relevant data are not yet published (e.g., bimagrumab plus semaglutide results, retatrutide body-composition data).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Phase 2 Study of Bimagrumab in Individuals with Obesity and Type 2 Diabetes [44]. In this 48-week study, adults with type 2 diabetes, body mass index between 28 and 40, and glycated hemoglobin (HbA1c) levels between 6.5% and 10.0% were randomly assigned to placebo or control at 9 US and UK sites. At 49 weeks, those assigned to bimagrumab had lost − 20.5% fat mass, gained + 3.6% lean mass and reduced HbA1c by 0.76 percentage points (P < 0.001 compared to placebo for all)](/paper-figures/a17d58593b8e43fa8731284054917e26/new-drugs-for-the-treatment-of-obesity-do-we-need-approaches-to-preserve-muscle-figure-1.jpg)
Verification
Claims the paper makes
25 Valid · 2 Not valid · 12 Not checked · 10 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“For semaglutide1, 74.8%, 54.8%, and 34.8% achieved those, while for tirzepatide [4] it was 90.1%, 78.2% and 62.9%.”
§ New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? > New developments in obesity pharmacotherapy – robust weight loss with the GLP- 1 receptor agonists for obesity > Weight loss efficacy
What the sources say
- Disputedcites [1] Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. sourceExperimental — accuracy not yet measured
The Change in Body Weight section reports the same ≥10%, ≥15%, and ≥20% benchmarks at week 68, but gives 69.1%, 50.5%, and 32.0% for the semaglutide group, respectively. None of the three percentages attributed to this paper matches those results. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even in older persons with stable weight, muscle is replaced by fat over time [27, 28].”
§ New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? > Body composition effects of semaglutide and tirzepatide
What the sources say
- Could not verifycites [27] Yang YC, et al. Life-course trajectories of body mass index from adolescence to old age: Racial and educational disparities. Proc Natl Acad Sci USA. 2021;118:e2020167118. sourceExperimental — accuracy not yet measured
The Abstract describes weight and BMI stabilizing before declining in later life, and the Discussion describes the study’s focus on BMI trajectories. Neither passage addresses whether older people with stable weight lose muscle and gain fat; searches for muscle replacement and body composition found no such passage in our copy. (LLM, conf=0.76)
- Supportedcites [28] Alley DE, et al. A research agenda: the changing relationship between body weight and health in aging. J Gerontol A Biol Sci Med Sci. 2008;63(11):1257–9. source
The opening section states the claim directly: even when older persons' weight is stable, muscle is replaced by fat over time. The paper presents this as an average age-related pattern, citing studies 4 and 5. (LLM, conf=0.95)
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a glucagon-like peptide receptor agonist (GLP- 1 RA), was shown in STEP 1 to produce mean weight reduction from baseline to week 68 of − 14.9% for semaglutide versus − 2.4% for placebo, by treatment-policy or treatment-regimen estimand which is reported throughout this manuscript, except where noted [1].”
§ New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? > New developments in obesity pharmacotherapy – robust weight loss with the GLP- 1 receptor agonists for obesity > Weight loss efficacy
What the sources say
- Supportedcites [1] Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. source
The Change in Body Weight section reports estimated mean weight change at week 68 of −14.9% with semaglutide versus −2.4% with placebo under the treatment-policy estimand. The Abstract likewise identifies these as changes from baseline to week 68. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“since loss of muscle and bone accelerates and progresses past age 60.”
§ New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? > Abstract
What the sources say
- Could not verifycites [27] Yang YC, et al. Life-course trajectories of body mass index from adolescence to old age: Racial and educational disparities. Proc Natl Acad Sci USA. 2021;118:e2020167118. sourceExperimental — accuracy not yet measured
The Results report that BMI peaks between ages 50 and 69 and begins to decline after 70, but do not identify muscle or bone loss as the cause. Searches for the claimed muscle-and-bone loss and an age-60 threshold found no passage addressing either point. (LLM, conf=0.76)
- Partly supportedcites [28] Alley DE, et al. A research agenda: the changing relationship between body weight and health in aging. J Gerontol A Biol Sci Med Sci. 2008;63(11):1257–9. sourceExperimental — accuracy not yet measured
The opening section says muscle mass generally declines with age and that weight tends to decline after about 60, with older-age weight loss posing a greater risk of disproportionate muscle loss. It does not establish that muscle and bone loss both accelerate after 60; it says the age of accelerated body-composition change varies substantially among individuals. The discussion of bone loss concerns minimizing it during weight-loss treatment, not its age-related rate. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, there was improvement in A1c favoring bimagrumab (− 0.76% reduction) vs. placebo (− 0.04% reduction).”
§ New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? > Approaches targeting the myostatin-activin pathway inhibitors (MAPi)
What the sources say
- Partly supportedcites [46] Heymsfield SB, Coleman LA, Miller R, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4(1):e2033457. sourceExperimental — accuracy not yet measured
The Results (Table 2) report a 0.76-percentage-point HbA1c reduction with bimagrumab, but a 0.04-percentage-point increase—not a reduction—with placebo. The Discussion describes placebo as having a 0.04-percentage-point decrease, so the paper is internally inconsistent on that sign; its tabulated result does not support the citing sentence’s placebo figure. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
25 more claims · 10 with their cited sources checked
Create a free account to see all 49 claims and every source verdict.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 14
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In these patients, excessive loss of LM, particularly muscle mass, is crucial because it increases the risk of frailty, falls, and fractures [123,124].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [124]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“For semaglutide 1 , 74.8%, 54.8%, and 34.8% achieved those, while for tirzepatide [4] it was 90.1%, 78.2% and 62.9%.”
InfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Self-citationCardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 1×
“Metabolic dysfunction-associated steatohepatitis (MASH) is an attractive target for the medications under development, and two investigational unimolecular agents incorporate glucagon receptor agonism; survodutide [16], a dual GLP-1/GCG RA, and retatrutide [17], a triple GLP-1/GIP/GCG RA.”
Research works printed but not linked: 3
- le Roux CW, Steen O, Lucas KJ, Startseva E, Unseid Am Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162–73. · DOI · Paper page
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389(6):514–26. · DOI · Paper page
- Burmeister MA and Fincher TK. Recreational use of selective androgen receptor modulators. US Pharm. 2020; 45(60):15-1.
Cited by
GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review
Pantazopoulos, D., Gouveri, E., Papazoglou, D., & Παπάνας, Ν. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112924 · Cited by 48
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101681 · Cited by 30
Are we giving too much weight to lean mass loss?
Bolte, J., Smelter, A. A., & Norton, L. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102253 · Cited by 21
Fitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100205 · Cited by 14
“Other unproven, investigational approaches include combining GLP-1 based therapies with glucagon or amylin analogues to potentially lessen loss of lean mass [90].”
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“In these patients, excessive loss of LM, particularly muscle mass, is crucial because it increases the risk of frailty, falls, and fractures [123,124].”
Metadata
- Authors
- Ryan, D. H.
- Affiliations
- Pennington Biomedical Research Center (US)
- Corresponding author
- Ryan, Donna H.
- ORCID
- Ryan, Donna H.
- Venue
- Reviews in Endocrine and Metabolic Disorders
- Published
- 2025-05-05
- Volume
- 26
- Issue
- 5
- Pages
- 805-813
- ISSN
- 1389-9155 (ISSN-L)
- 1573-2606
- PMC
- PMC12534358
- OpenAlex
- W4410069635
- Cited by
- 34
- References
- 45
- Citations by year
- 2026: 17 · 2025: 17
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Reviews in Endocrine and Metabolic Disorders (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- obesity treatment, lean mass preservation, GLP-1 receptor agonists, semaglutide, tirzepatide, glucagon, amylin, bimagrumab, body composition, weight loss, older adults, disease modification, cardiovascular risk reduction, obstructive sleep apnea, diabetes management, heart failure, chronic kidney disease
- MeSH terms
- Humans, Obesity, Muscle, Skeletal, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? https://app.cochat.ai/papers/10.1007/s11154-025-09967-4
- The paper
- Ryan, D. H. (2025). New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-025-09967-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.